Published in Drugs Aging on October 01, 1999
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis (2003) 1.46
Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res (2015) 0.78
Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma. Front Oncol (2015) 0.78
Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing. Immunology (2014) 0.76
Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw. J Transl Med (2015) 0.76
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol (2000) 2.47
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
The time course of a hypercalcaemic crisis in acute primary hyperparathyroidism. Lancet (1984) 2.21
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int (2005) 1.80
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care (2001) 1.74
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Bone loss in response to long-term glucocorticoid therapy. Bone Miner (1990) 1.44
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab (1999) 1.43
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int (2003) 1.36
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
Radioimmunoassay of 1,25-dihydroxy vitamin D2: studies on the metabolism of vitamin D2 in man. Clin Endocrinol (Oxf) (1983) 1.13
Hypomagnesaemia: studies of parathyroid hormone secretion and function. Clin Endocrinol (Oxf) (1984) 1.08
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis (2004) 1.06
Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int (2007) 1.03
Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. Bone (2004) 1.02
[Incidence and socioeconomic burden of hip fractures in Italy]. Reumatismo (2005) 1.02
Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol (1985) 1.02
Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis (2007) 1.01
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int (2013) 1.00
Relation between adiponectin and bone mineral density in elderly post-menopausal women: role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate. J Endocrinol Invest (2008) 1.00
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int (2001) 0.96
Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men. Calcif Tissue Int (2002) 0.95
Age-related cortical bone loss at the metacarpal. Calcif Tissue Int (1997) 0.95
Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res (1994) 0.94
Association of CTR and COLIA1 alleles with BMD values in peri- and postmenopausal women. Calcif Tissue Int (2000) 0.93
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res (2001) 0.93
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int (1986) 0.92
Familial benign hypercalcaemia. Study of a large family. Q J Med (1983) 0.91
Cytochemical bioassay of parathyroid hormone in maternal and cord blood. Arch Dis Child (1985) 0.88
Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res (2000) 0.88
New perspectives on the definition and the management of severe osteoporosis: the patient with two or more fragility fractures. J Endocrinol Invest (2009) 0.88
Quantitative ultrasound calcaneous measurements: normative data for the Italian population. the ESOPO study. J Clin Densitom (2007) 0.87
Bone loss after glucocorticoid therapy. Calcif Tissue Int (1984) 0.86
Interferential and horizontal therapies in chronic low back pain: a randomized, double blind, clinical study. Clin Exp Rheumatol (2006) 0.85
Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis. Clin Exp Rheumatol (2005) 0.84
Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol (2007) 0.84
Quantitative ultrasound in adults with cystic fibrosis: correlation with bone mineral density and risk of vertebral fractures. Calcif Tissue Int (2007) 0.84
Osteoporosis in men--consensus is premature. Calcif Tissue Int (2004) 0.84
Association between bone mineral density and serum lipids in men. JAMA (2001) 0.83
Interferential and horizontal therapies in chronic low back pain due to multiple vertebral fractures: a randomized, double blind, clinical study. Osteoporos Int (2007) 0.82
Control of secretion of parathyroid hormone in secondary hyperparathyroidism. Clin Endocrinol (Oxf) (1982) 0.82
Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone (1999) 0.82
Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. Clin Chim Acta (1998) 0.82
Influence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women. Bone Miner (1993) 0.82
Association of quantitative heel ultrasound with history of osteoporotic fractures in elderly men: the ESOPO study. Osteoporos Int (2005) 0.82
Adherence to therapeutic and diagnostic recommendations in patients with femur fracture and at risk of re-fracture or death: results of an analysis of administrative databases. Reumatismo (2012) 0.82
Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther (2000) 0.82
Radial bending breaking resistance derived by densitometric evaluation predicts femoral neck fracture. Osteoporos Int (2001) 0.82
Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience. Clin Exp Rheumatol (2011) 0.81
Bone mineral density in children and adolescent females treated with high doses of L-thyroxine. Horm Res (1993) 0.81
Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int (2008) 0.80
Acute effects of deflazacort and prednisone on rates of mineralization and bone formation. Calcif Tissue Int (1995) 0.80
Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy. Reumatismo (2013) 0.80
Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis (2000) 0.80
Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest (1997) 0.79
A carboxy-terminal specific assay for human parathyroid hormone. Clin Endocrinol (Oxf) (1981) 0.79
Somatostatin inhibition of insulin secretion in insulin-producing tumors. Metabolism (1976) 0.79
Bone loss in the elderly. Osteoporos Int (1994) 0.79
[Risk factors for hip fracture in elderly persons]. Reumatismo (2011) 0.79
Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone (2000) 0.79
Calcium-sensing receptor gene polymorphism is not associated with bone mineral density in Italian postmenopausal women. Eur J Endocrinol (2003) 0.78
Discriminant analysis in the differential diagnosis of hypercalcaemia. Clin Endocrinol (Oxf) (1978) 0.78
Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone (2003) 0.78
Evidence for extrarenal metabolism of 25-hydroxyvitamin D3 in man. Clin Sci (Lond) (1986) 0.78
Instrumental diagnosis of osteoporosis. Aging (Milano) (1998) 0.78
Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo (2016) 0.78
Substrate-product relation of 1-hydroxylase activity in primary hyperparathyroidism. N Engl J Med (1985) 0.77
Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur J Endocrinol (1995) 0.77
Genetics of osteoporosis. Calcif Tissue Int (1994) 0.77
Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol (1986) 0.77
[Pain patterns in Italian patients with osteoarthritis: preliminary results of the MI.D.A. Study (Misurazione del Dolore nell'Artrosi)]. Reumatismo (2005) 0.77
Evaluation of cortical thickness and bone density by roentgen microdensitometry in growing males and females. Eur J Pediatr (1996) 0.77
Effect of aging on trabecular and compact bone components of proximal and ultradistal radius. Osteoporos Int (1996) 0.76
Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP). Metab Bone Dis Relat Res (1984) 0.76
Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment. Calcif Tissue Int (1982) 0.76
Circulating concentrations of 1,25-dihydroxyvitamin D3 in patients with primary hyperparathyroidism. Bone Miner (1986) 0.76
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? Reumatismo (2015) 0.76
Vitamin D and rheumatic diseases. Reumatismo (2014) 0.76
Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study. Clin Exp Rheumatol (2007) 0.76
Duration of treatment for osteoporosis. Reumatismo (2013) 0.76
[Vitamin D and fractures: a systematic review]. Reumatismo (2007) 0.75
Extrarenal synthesis of 1,25-dihydroxyvitamin D: sensitivity to glucocorticoid treatment. Clin Sci (Lond) (1987) 0.75
Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies. Br Med J (Clin Res Ed) (1984) 0.75
Comment on calcium-regulated renal calcium handling in healthy men. J Clin Endocrinol Metab (1999) 0.75
[Rational and results of weekly treatment with calcidiol in postmenopausal and senile osteoporosis]. Minerva Med (2007) 0.75
[Diacetylrhein in the treatment of degenerative arthropathies]. Clin Ter (1985) 0.75
Simultaneous measurement of 1.25-dihydroxy-vitamin D, 24.25-dihydroxy-vitamin D and 25-hydroxy-vitamin D from a single two milliliters serum specimen. Preliminary clinical application. J Endocrinol Invest (1984) 0.75